消化系醫學論文

Publications of Gastroenterology and Hepatology Division in 2022

¹ :  表此篇文章以榮總之名義發表

² :  表此篇文章以榮總及陽明之名義發表

³ :  表此篇文章為國外進修時之著作

⁴ :  表此篇文章之第一作者為本部其它科之醫師

⁵ : 表此篇文章之第一作者為本院其它部科或他院之醫師

*:  為通訊作者

A. Refereed Papers Included in Science Citation Index:

1. ²⁵Bai LY, Li CP, Shan YS, Chuang SC, Chen JS, Chiang NJ, Chen YY, Tsou HH, Chuang MH, Chiu CF, Liu TW, Chen LT*. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - The Taiwan Cooperative Oncology Group T1217 study. Eur J Cancer 2022;173():123-132. (IF:10.002)
2. ²⁵Chang SH, Lin PY, Wu TK, Hsu CS, Huang SW, Li ZY, Liu KT, Kao JK, Chen YJ, Wong TW, Wu CY*, Shieh JJ*. Imiquimod-induced ROS production causes lysosomal membrane permeabilization and activates caspase-8-mediated apoptosis in skin cancer cells. J Dermatol Sci 2022;107(3):142-150. (IF:5.408)
3. ¹²Chang TE, Su CW*, Huang YS, Huang YH, Hou MC, Wu JC*. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. J Chin Med Assoc 2022;85(1):30-41. (IF:3.396)
4. ¹²Chang YS, Su CW, Chen SC, Chen YY, Liang YJ, Wu JC*. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. Cells 2022;11(4):-. (IF:7.666)
5. ²⁵Chen JY, Hsieh SM, Hwang SJ, Liu CS, Li XL*, Fournier M, Yeh TY, Yin JK, Samson SI. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study. Vaccine 2022;40(45):6450-6454. (IF:4.169)
6. ¹²Chen SC, Huang YH, Chen MH, Hung YP, Lee RC, Shao YY, Chao Y*. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer 2022;22(1):-. (IF:4.638)
7. ²⁵Chen YC, Chang TS, Chen CH, Cheng PN, Lo CC, Mo LR, Chen CT, Huang CF, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Dai CY, Kao JH, Chuang WL, Lin HC, Chen CY, Tseng KC*, Yu ML*. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses-Basel 2022;14(2):-. (IF:5.818)
8. ¹²Chen YJ, Su CW, Wei CY, Chau GY, Chen PH, Chao Y, Huang YH, Wu JC, Yang TC, Lee PC, Hou MC*. Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. J Chin Med Assoc 2022;85(6):679-686. (IF:3.396)
9. ²⁵Chen YY, Hsueh SW, Yang SH, Chiu SC, Chiang NJ, Chiu TJ, Li CP, Bai LY, Chiu CF, Chuang SC, Shan YS, Chan DCA, Chen LT, Yen CJ, Peng CM, Chen JS, Chou WC*. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Am J Cancer Res 2022;12(9):4267-4278. (IF:5.942)
10. ²⁵Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, Lo CC, Tseng KC, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang T, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Chou KH, Kao CN, Tsai PC, Liu CH, Lee MH, Cheng CY, Tsai MC, Liu CJ, Dai CY, Lin HC*, Kao JH, Chuang WL, Yu ML*. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. Infect Dis Ther 2022;11(1):485-500. (IF:6.119)
11. ¹²Chiang CH, Chang CC, Huang HC, Chen YJ, Tsai PH, Jeng SY, Hung SI, Hsieh JH, Huang HS, Chiou SH*, Lee FY*, Lee SD. Investigation of Hepatoprotective Activity of Induced Pluripotent Stem Cells in the Mouse Model of Liver Injury (vol 2011, 219060, 2011). Biomed Res Int 2022;2022():-. (IF:3.246)
12. ¹²⁴Chiang DH, Chen CT, Wang TY, Yang YY*, Huang CC, Li TH, Huang SS, Kao SY, Chen CH, Hou MC, Sheu WHH. Enhancing the learning and transfer of preprocedural communication skills during clerkship using audio-visual material: a prospective case-controlled study over 2 years. BMJ Open 2022;12(1):-. (IF:3.006)
13. ¹²⁴Chiang NJ, Tan KT*, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT*, Chen MH*. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clin Cancer Res 2022;28(19):4248-4257. (IF:13.801)
14. ²⁵Chiu TJ, Yang SH, Chiu SC, Hsueh SW, Chiang NJ, Li CP, Bai LY, Cheng FM, Chuang SC, Shan YS, Chan DC, Chen LT, Yen CJ, Peng CM, Su YY, Chen YY, Chen JS, Chou WC*. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin. J Hepato-Biliary-Pancreat Sci 2022;29(6):670-681. (IF:3.149)
15. ²⁵D'Alessio A, Fulgenzi CAM, Nishida N, Schonlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu LD, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ*. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology 2022;76(4):1000-1012. (IF:17.298)
16. ¹²Guo JY, Chen HH, Lee WJ, Chen SC, Lee SD, Chen CY*. Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass. Nutrients 2022;14(3):-. (IF:6.706)
17. ²⁵Ho SE, Liu PH, Hsu CY, Huang YH, Liao J, Su CW, Hou MC, Huo TA*. Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Expert Rev Gastroenterol Hepatol 2022;16(9):903-911. (IF:4.095)
18. ¹²Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI*. A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers 2022;14(3):-. (IF:6.575)
19. ¹²Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score. Cancers 2022;14(17):-. (IF:6.575)
20. ¹²Ho SY, Yuan MH, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Wang CL, Hou MC, Huo TL*. Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scand J Gastroenterol 2022;():-. (IF:3.027)
21. ¹²Hsieh YC, Wu PS, Lin YT, Huang YH, Hou MC, Lee KC*, Lin HC. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. Faseb J 2022;36(10):-. (IF:5.834)
22. ²⁵Hsu CH, Huang YH, Lin SM*, Hsu C*. AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review. Liver Cancer 2022;11(2):94-112. (IF:12.430)
23. ¹²Hsu SJ, Huang HC, Pun CK, Chang CC*, Chuang CL, Huang YH, Hou MC, Lee FY. Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats. J Pharmacol Exp Ther 2022;383(1):25-31. (IF:4.404)
24. ²⁵Huang CF, Tseng KC, Cheng PN, Hung CH, Lo CC, Peng CY, Bair MJ, Yeh ML, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Lin CL, Wang CC, Yang SS, Mo LR, Chen GY, Chang CC, Wang SJ, Huang CS, Hsieh TY, Lin CW, Lee TH, Chong LW, Huang CW, Chang SN, Tsai MC, Hsu SJ, Kao JH, Liu CJ, Liu CH, Lin HC, Lee MH, Tsai PC, Dai CY, Chuang WL, Chen CY*, Yu ML*. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). Clin Gastroenterol Hepatol 2022;20(5):1151-+. (IF:13.576)
25. ¹²Huang HC, Hsu SJ, Chang CC*, Chuang CL, Hou MC, Lee FY. Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. Int J Mol Sci 2022;23(13):-. (IF:6.208)
26. ¹²Huang HC, Hsu SJ, Chang CC*, Kao YC, Chuang CL, Hou MC, Lee FY. Lycopene treatment improves intrahepatic fibrosis and attenuates pathological angiogenesis in biliary cirrhotic rats. J Chin Med Assoc 2022;85(4):414-420. (IF:3.396)
27. ¹²Huang HC, Sung YC, Li CP, Wan DH, Chao PH, Tseng YT, Liao BW, Cheng HT, Hsu FF, Huang CC, Chen YT, Liao YH, Hsieh HT, Shih YC, Liu IJ, Wu HC, Lu TT*, Wang J*, Chen YC*. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours. Gut 2022;71(9):1843-1855. (IF:31.793)
28. ²⁴Huang HH, Lin TL, Lee WJ, Chen SC, Lai WF, Lu CC, Lai HC*, Chen CY*. Impact of Metabolic Surgery on Gut Microbiota and Sera Metabolomic Patterns among Patients with Diabetes. Int J Mol Sci 2022;23(14):-. (IF:6.208)
29. ¹²Huang KW, Lee PC, Chao Y, Su CW, Lee IC, Lan KH, Chu CJ, Hung YP, Chen SC, Hou MC, Huang YH*. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14():-. (IF:5.485)
30. ¹²Huang YS*, Tseng SY, Chen WW, Chang TT, Peng CY, Lo GH, Hsu CW, Hu CT, Huang YH. Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection. J Chin Med Assoc 2022;85(3):286-294. (IF:3.396)
31. ¹²Huo TI*, Ho SY, Liao JI. Improving the accuracy of outcome prediction for hepatocellular carcinoma: Asia strategies. Liver Int 2022;42(3):714-715. (IF:8.754)
32. ¹²Huo TI*, Ho SY, Liao JI. Comment on: Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. Br J Surg 2022;109(11):E119-E119. (IF:11.782)
33. ¹²Huo TI*, Ho SY, Liao JI. A commentary on "Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study" (Int J Surg 2022;105:106843). Int J Surg 2022;106():-. (IF:13.400)
34. ¹²Huo TI*, Ho SY, Liao JI. Look for new biomarkers in the management of hepatocellular carcinoma: What the hepatologists may need to know. Liver Int 2022;():-. (IF:8.754)
35. ¹²Huo TI*, Liao JI, Ho SY. Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?. J Hepatol 2022;76(4):987-988. (IF:30.083)
36. ¹²Huo TL*, Liao JI, Ho SY. 3-Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor?. Liver Int 2022;42(6):1475-1475. (IF:8.754)
37. ¹²Jheng YC, Wang YP, Lin HE, Sung KY, Chu YC, Wang HS, Jiang JK, Hou MC, Lee FY, Lu CL*. A novel machine learning-based algorithm to identify and classify lesions and anatomical landmarks in colonoscopy images. Surg Endosc 2022;36(1):640-650. (IF:3.453)
38. ²⁵Kao WY, Su CW*. Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?. Liver Int 2022;42(12):2597-2598. (IF:8.754)
39. ¹²Ko CC, Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, Lei HJ, Lee RC, Hou MC, Huo TI*. Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade. Int J Clin Oncol 2022;27(4):739-748. (IF:3.850)
40. ²⁵Kuo CW, Wu HL, Li CC, Cata JP, Liu HY, Hou MC, Cherng YG, Tai YH*. Long-Term Survival Impact of High-Grade Complications after Liver Resection for Hepatocellular Carcinoma: A Retrospective Single-Centre Cohort Study. Med Lith 2022;58(4):-. (IF:2.948)
41. ¹²Lee CY, Chau GY, Wei CY, Chao Y, Huang YH, Huo TI, Hou MC, Su YH, Wu JC, Su CW*. Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. Sci Rep 2022;12(1):-. (IF:4.996)
42. ¹²Lee IC, Chao Y, Lee PC, Chen SC, Chi CT, Wu CJ, Wu KC, Hou MC, Huang YH*. Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers 2022;14(8):-. (IF:6.575)
43. ¹²Lee IC*, Lan KH, Su CW, Li CP, Chao Y, Lin HC, Hou MC, Huang YH*. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. Int J Mol Sci 2022;23(19):-. (IF:6.208)
44. ¹²Lee IC*, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, Su CW, Hou MC, Huang YH*. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. Viruses-Basel 2022;14(11):-. (IF:5.818)
45. ¹²Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC*. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection. J Formos Med Assoc 2022;121(9):1636-1646. (IF:3.871)
46. ¹²Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH*. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022;10(6):-. (IF:12.469)
47. ²⁵Lee SW, Chen LS, Yang SS, Huang YH, Lee TY*. Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma. Viruses-Basel 2022;14(11):-. (IF:5.818)
48. ¹²Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC, Su YH, Wu JC, Su CW*. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc 2022;85(5):554-565. (IF:3.396)
49. ²⁵Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN*. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022;121(10):2085-2092. (IF:3.871)
50. ²⁵Liu CJ*, Sheen IS, Chen CY, Chuang WL, Wang HY, Tseng KC, Chang TT, Yang J, Massetto B, Suri V, Camus G, Jiang DY, Zhang FQ, Gaggar A, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. Clin Infect Dis 2022;75(3):453-459. (IF:20.999)
51. ¹²Liu YC, Su CW, Ko PS, Lee RC, Liu CJ, Huang YH, Gau JP, Liu JH*. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. Asia-Pac J Clin Oncol 2022;18(1):19-27. (IF:1.926)
52. ¹²Lo CC, Huang CF, Cheng PN, Tseng KC, Chen CY, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Chuang WL, Lin HC, Kao JH*, Yu ML*, Investigators. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. J Formos Med Assoc 2022;121(8):1567-1578. (IF:3.871)
53. ¹²Lu HS, Yang TC, Chang CY, Huang YH, Hou MC*. The risk of variceal bleeding during endoscopic retrograde cholangiopancreatography. J Chin Med Assoc 2022;85(9):896-900. (IF:3.396)
54. ²⁵Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T*. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 2022;10(6):-. (IF:12.469)
55. ²⁵Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun TM, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang YH, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ*. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers 2022;14(1):-. (IF:6.575)
56. ¹²Pan YL, Wu PS*, Ye BW, Li CP, Lee IC, Lee KC*, Huang YH, Hou MC. Outcomes of patients with malignant esophagogastric junction obstruction receiving metallic stents: A single-center experience. J Chin Med Assoc 2022;85(2):160-166. (IF:3.396)
57. Sarin SK*, Eslam M, Fan JG, Lin HC*, George J, Omata M. MAFLD, patient-centred care, and APASL. Hepatol Int 2022;16(5):1032-1034. (IF:9.046)
58. Sharma R*, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang YH, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH*, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 2022;6(7):1776-1785. (IF:5.701)
59. ¹Su PS, Wu SH, Chu CJ*, Su CW, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. J Chin Med Assoc 2022;85(2):152-159. (IF:3.396)
60. ²⁵Su YY, Chiang NJ, Li CP, Yen CJ, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chuang SC, Bai LY, Chiu CF, Peng CM, Chan DC, Chiu SC, Yang YH, Shan YS*, Chen LT*. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Front Oncol 2022;12():-. (IF:5.738)
61. ²⁵Su YY, Chiu YF, Li CP, Yang SH, Lin OO, Lin E, Chang PY, Chiang NJ, Shan YS*, Ch'ang HJ*, Chen LZ*. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. Br J Cancer 2022;126(7):1018-1026. (IF:9.075)
62. ¹²Sung KI, Wang YP*, Chang TE, Wang HS, Jiang JK, Luo JC, Lee FY, Hou MC, Lu CL. Safety and importance of colonoscopy in nonagenarians. J Chin Med Assoc 2022;85(3):304-310. (IF:3.396)
63. ¹²Sung KY, Chang TE, Wang YP*, Lin CC, Chang CY, Hou MC, Lu CL. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis. J Chin Med Assoc 2022;85(4):421-430. (IF:3.396)
64. ¹²Sung KY, Zhang B, Wang HHE, Bai YM, Tsai SJ, Su TP, Chen TJ, Hou MC, Lu CL, Wang YP*, Chen MH*. Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study. Aliment Pharmacol Ther 2022;55(9):1192-1201. (IF:9.524)
65. ¹²⁴Tsai CF, Chuang CH, Wang YP, Lin YB, Tu PC, Liu PY, Wu PS, Lin CY, Lu CL*. Differences in gut microbiota correlate with symptoms and regional brain volumes in patients with late-life depression. Front Aging Neurosci 2022;14():-. (IF:5.702)
66. ¹²Tsai HC, Tung HY, Liu CW, Su CF, Sun YS, Chen WS, Chen MH, Lai CC, Liao HT*, Yang YY, Huang YH, Tsai CY*. Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease-a retrospective investigation of 845 patients and its clinical relevance. Clin Rheumatol 2022;41(1):115-122. (IF:3.650)
67. ²Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schonlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu LD, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R*. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. Liver Int 2022;42(11):2538-2547. (IF:8.754)
68. ¹²⁵Wang HW, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, Yu ML*, Peng CY*. Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study. Am J Cancer Res 2022;12(7):3164-+. (IF:5.942)
69. ¹²⁵Wang HW, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, Yu ML*, Peng CY*. Original Article Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study. Am J Cancer Res 2022;12(7):3164-+. (IF:5.942)
70. ¹²Wang YP, Jheng YC, Sung KY, Lin HE, Hsin IF, Chen PH, Chu YC, Lu D, Wang YJ, Hou MC, Lee FY, Lu CL*. Use of U-Net Convolutional Neural Networks for Automated Segmentation of Fecal Material for Objective Evaluation of Bowel Preparation Quality in Colonoscopy. Diagnostics 2022;12(3):-. (IF:3.992)
71. ¹²Wei TH, Ye BW, Wu PS*, Li CP, Chao Y, Lee PC, Huang YH, Lee KC*, Hou MC. Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. PLoS One 2022;17(5):-. (IF:3.752)
72. ¹²⁵Wen MH, Bai D, Lin S, Chu CJ, Hsu YL. Implementation and experience of an innovative smart patient care system: a cross-sectional study. BMC Health Serv Res 2022;22(1):-. (IF:2.908)
73. ¹²Wu CJ, Lee PC, Hung YW, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH*. Lenvatinib plus pembrolizumab for systemic therapy-naive and -experienced unresectable hepatocellular carcinoma. Cancer Immunol Immunother 2022;71(11):2631-2643. (IF:6.630)
74. ¹²⁵Wu CY*, Wu CY*, Li CP, Lin YH, Chang YT. Association of Immunosuppressants with Mortality of Patients with Bullous Pemphigoid: A Nationwide Population-Based Cohort Study. Dermatology 2022;238(2):378-385. (IF:5.197)
75. ¹²⁵Wu HL, Liu HY, Liu WC, Hou MC, Tai YH*. A predictive model incorporating inflammation markers for high-grade surgical complications following liver resection for hepatocellular carcinoma. J Chin Med Assoc 2022;85(8):845-852. (IF:3.396)
76. ¹²Wu JW, Cheng HM, Huang SS, Liang JF, Huang CC, Shulruf B, Yang YY*, Chen CH*, Hou MC, Sheu WHH. Medical school grades may predict future clinical competence. J Chin Med Assoc 2022;85(9):909-914. (IF:3.396)
77. ¹²⁵Wu JW, Cheng HM, Huang SS, Liang JF, Huang CC, Yang LY, Shulruf B, Yang YY*, Chen CH, Hou MC, Sheu WHH. Comparison of OSCE performance between 6-and 7-year medical school curricula in Taiwan. BMC Med Educ 2022;22(1):-. (IF:3.263)
78. ¹²⁵Wu WC, Lin TY, Chen MH, Hung YP, Liu CA, Lee RC, Huang YH, Chao Y, Chen SC*. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs 2022;40(4):789-797. (IF:3.651)
79. ¹²⁵Wu YH, Hung YP, Chiu NC, Lee RC, Li CP, Chao Y, Shyr YM, Wang SE, Chen SC, Lin SH, Chen YH, Kang YM, Hsu SM, Yen SH, Wu JY, Lee KD, Tseng HE, Tsai JR, Tang JH, Chiou JF, Burnouf T, Chen YJ, Wang PY, Lu LS*. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. Eur J Cancer 2022;166():208-218. (IF:10.002)
80. ¹⁵Yang AM*, Lin CY, Liu SH, Syu GD, Sun HJ, Lee KC*, Lin HC, Hou MC. Saccharomyces Boulardii Ameliorates Non-alcoholic Steatohepatitis in Mice Induced by a Methionine-Choline-Deficient Diet Through Gut-Liver Axis. Front Microbiol 2022;13():-. (IF:6.064)
81. ¹²⁵Yang SH, Chiang NJ, Chiu SC, Chou WC, Bai LY, Li CP, Su YY, Chiu TJ, Chuang SC, Peng CM, Chan DC, Chen JS, Yen CJ, Chen YY, Chiu CF, Chen LT, Shan YS*. Original Article The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Am J Cancer Res 2022;12(4):1884-1898. (IF:5.942)
82. ¹²Yang TC, Chen PH, Hou MC*, Peng LN, Lin MH, Chen LK, Huang YH. Antiperistaltic effect and safety of l-menthol for esophagogastroduodenoscopy in the elderly with contraindication to hyoscine-N-butylbromide. Sci Rep 2022;12(1):-. (IF:4.996)
83. ¹²⁵Yang YP, Lee ACL, Lin LT, Chen YW, Huang PI, Ma HI, Chen YC, Lo WL, Lan YT, Fang WL, Wang CY, Liu YY, Hsu PK, Lin WC, Li CP, Chen MT, Chien CS*, Wang ML*. Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects. Cancers 2022;14(3):-. (IF:6.575)
84. ²Yau T*, Tai DV, Chan SL, Huang YH*, Choo SP, Hsu C, Cheung TT, Lin SM, Yong WP, Lee JYY, Leung T, Shum T, Yeung CSY, Tai AYP, Law ALY, Cheng AL, Chen LT. Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. Liver Cancer 2022;11(5):426-439. (IF:12.430)
85. ¹²Ye YC, Wang SE, Wang YP*. Ileoileal Intussusception Caused by Ileal Neuroendocrine Carcinoma. Clin Gastroenterol Hepatol 2022;20(9):XXIX-XXX. (IF:13.576)
86. ²⁵Yen FS, Hsu CC, Wei JCC, Hou MC*, Hwu CM*. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Front Med 2022;9():-. (IF:5.058)
87. ²⁵Yen FS, Huang YH, Hou MC, Hwu CM, Lo YR, Shin SJ, Hsu CC*. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. Br J Clin Pharmacol 2022;88(1):311-322. (IF:3.716)
88. ¹⁵You H, Ma X, Efe C, Wang GQ, Jeong SH, Abe K, Duan WJ, Chen S, Kong YY, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou JL, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia JD. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022;16(1):1-23. (IF:9.029)
89. ¹⁵Yu HY, Lee CY, Lin LG, Chao Y, Li CP*. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. J Chin Med Assoc 2022;85(1):42-50. (IF:3.396)
90. ¹⁵Yu HY, Li CP, Huang YH, Hsu SJ, Wang YP, Hsieh YC, Fang WL, Huang KH, Li AFY, Lee RC, Lee KL, Wu YH, Lai IC, Yang WC, Hung YP, Wang YC, Chen SH, Chen MH*, Chao Y*. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers 2022;14(1):-. (IF:6.575)
91. ²Zhang B*, Wang HHE, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP*, Chen MH*. Bidirectional association between inflammatory bowel disease and depression among patients and their unaffected siblings. J Gastroenterol Hepatol 2022;37(7):1307-1315. (IF:4.369)
92. ²⁵Liao YL, Wang TJ*, Su CW, Liang SY, Liu CY, Fan JY. Efficacy of a Decision Support Intervention on Decisional Conflict Related to Hepatocellular Cancer Treatment: A Randomized Controlled Trial. Clin Nurs Res 2022;():-. (IF:1.724)
93. ¹²Huang HC, Chang CC, Pun CK, Tsai MH, Chuang CL, Hsu SJ*, Huang YH, Hou MC, Lee FY.. α-Adrenergic blockade prevented environmental temperature reduction-induced transient portal pressure surge in cirrhotic and portal hypertensive rats. Clin Sci (Lond). 2022 Oct 28;136(20):1449-1466.. 　　;　:　. (IF:6.876)
94. ¹⁵Rajappa S, Rau KM, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH*.. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? World J Hepatol. 2022 Jun 27;14(6):1074-1086. (IF:3.173)